Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2018

  • ID: 4473134
  • Drug Pipelines
  • 120 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma SA
  • Minerva Neurosciences Inc
  • Pfizer Inc
  • Puma Biotechnology Inc
  • XuanZhu Pharma Co Ltd
  • MORE
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H1 2018'; Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.

The report 'Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H1 2018' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 4, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Non-Small Cell Lung Cancer, Gastric Cancer, Metastatic Breast Cancer, Solid Tumor, Esophageal Cancer, Breast Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Bile Duct Cancer (Cholangiocarcinoma), Lung Adenocarcinoma, Metastatic Brain Tumor, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ependymoma, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Low-Grade Astrocytoma, Low-Grade Glioma, Lung Cancer, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary Tumor, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Malignant Glioma, Rhabdomyosarcoma, Skin Cancer, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics
Reasons to Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma SA
  • Minerva Neurosciences Inc
  • Pfizer Inc
  • Puma Biotechnology Inc
  • XuanZhu Pharma Co Ltd
  • MORE
Introduction

Report Coverage

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Aslan Pharmaceuticals Pte Ltd

Boehringer Ingelheim GmbH

GamaMabs Pharma SA

Hanmi Pharmaceuticals Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Minerva Neurosciences Inc

Pfizer Inc

Puma Biotechnology Inc

Shanghai Fosun Pharmaceutical (Group) Co Ltd

XuanZhu Pharma Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dacomitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-5209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIN-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neucardin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRG-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-113 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-357 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKLB-1206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varlitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5491 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yinlitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer

Jan 31, 2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018

Jan 23, 2018: Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Jan 18, 2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China

Jan 18, 2018: QIAGEN receives FDA approval to expand use of EGFR test in lung cancer

Jan 16, 2018: FDA approves new indication for Gilotrif in EGFR mutation-positive NSCLC

Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China

Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2

Dec 13, 2017: Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Dec 12, 2017: Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer

Dec 11, 2017: Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings

Dec 06, 2017: Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

Nov 13, 2017: Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology

Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2

Nov 02, 2017: Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pipeline by GamaMabs Pharma SA, H1 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2018

Pipeline by Minerva Neurosciences Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Puma Biotechnology Inc, H1 2018

Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H1 2018

Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aslan Pharmaceuticals Pte Ltd
  • Boehringer Ingelheim GmbH
  • GamaMabs Pharma SA
  • Hanmi Pharmaceuticals Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Minerva Neurosciences Inc
  • Pfizer Inc
  • Puma Biotechnology Inc
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • XuanZhu Pharma Co Ltd
  • Zensun (Shanghai) Sci & Tech Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll